Partner Organisation
BRUKER DALTONICS GMBH & CO KG
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
MSAID GmbH
MSAID GmbH [ɛm ɛs eɪd] transforms the way scientists analyze proteomics data. MSAID is a privately-held informatics spin-off from the Chair of Proteomics and Bioanalytics at the Technical University of Munich, Germany. The company was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. Our team members have an exceptionally strong track record and long-standing expertise in the acquisition, analysis, and interpretation of proteomics data. As the leader in proteomics artificial intelligence, we replace current algorithms with powerful, AI-based solutions such as INFERYS and CHIMERYS and pave the way for a deeper, and more reliable way of interrogating proteomics data.
AstraZeneca
AstraZeneca is a global pharmaceutical company dedicated to developing innovative treatments that improve the lives of millions of patients and bring value to healthcare systems. With over 25 years of history and a strong record of scientific success, the company has contributed to ten Nobel Prizes. Worldwide, AstraZeneca employs more than 94,300 people. Headquartered in Cambridge, United Kingdom, it operates in over 130 countries, and its innovative medicines benefit more than 134 million patients globally. The company pushes the boundaries of science to deliver life-changing medicines and enhance healthcare systems. It focuses on the small details that create meaningful impact and make a real difference. Driven by science, AstraZeneca concentrates its efforts on five key therapeutic areas to accelerate new solutions for unmet medical needs: Oncology, CVRM (Cardiovascular, Renal and Metabolism), Respiratory and Immunology, Vaccines and Immunotherapies, and Rare Diseases.